Liquid Biopsy

Shares of Biocept (NASDAQ: BIOC) have been volatile since the company made its debut as a public company in early February. In an exclusive interview with Benzinga, CEO Michael Nall and CFO Bill Kachioff laid out the company’s opportunities and events investors should watch for in the...